Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “buy” rating reissued by stock analysts at Wells Fargo in a research note issued to investors on Wednesday.
AMPH has been the topic of a number of other reports. BidaskClub raised Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, January 19th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Needham & Company LLC lifted their target price on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 1st. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 target price on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $21.33.
Shares of AMPH stock opened at $19.51 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79. The firm has a market capitalization of $901.06, a P/E ratio of 216.78, a price-to-earnings-growth ratio of 1.38 and a beta of 1.46. Amphastar Pharmaceuticals has a 1-year low of $13.15 and a 1-year high of $20.45.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Monday, March 12th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.03. The company had revenue of $60.40 million for the quarter, compared to the consensus estimate of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The company’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.01 earnings per share. equities research analysts predict that Amphastar Pharmaceuticals will post 0.63 EPS for the current fiscal year.
In other news, CFO William J. Peters sold 19,801 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total value of $398,000.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard K. Prins sold 16,598 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $19.90, for a total transaction of $330,300.20. Following the completion of the transaction, the director now owns 45,442 shares of the company’s stock, valued at approximately $904,295.80. The disclosure for this sale can be found here. Insiders sold 84,387 shares of company stock valued at $1,659,763 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $400,000. BNP Paribas Arbitrage SA raised its position in Amphastar Pharmaceuticals by 70.2% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock worth $321,000 after purchasing an additional 7,401 shares during the last quarter. Prudential Financial Inc. raised its position in Amphastar Pharmaceuticals by 8.3% in the 3rd quarter. Prudential Financial Inc. now owns 63,580 shares of the company’s stock worth $1,136,000 after purchasing an additional 4,850 shares during the last quarter. Fisher Asset Management LLC raised its position in Amphastar Pharmaceuticals by 8.1% in the 4th quarter. Fisher Asset Management LLC now owns 229,277 shares of the company’s stock worth $4,411,000 after purchasing an additional 17,094 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 17.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after purchasing an additional 226,271 shares during the last quarter. Institutional investors own 44.82% of the company’s stock.
WARNING: “Wells Fargo Reiterates Buy Rating for Amphastar Pharmaceuticals (AMPH)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/22/wells-fargo-reiterates-buy-rating-for-amphastar-pharmaceuticals-amph.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.